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Summary Enzymatic, and microbiological assays were used to determine the hepatic contents of coenzyme
A, acetyl CoA, fatty acid synthetase activity, and pantothenate in livers of tumour-bearing mice. Significant
decreases in CoA and acetyl CoA were found in mice bearing TLX-5 lymphoma, sarcoma 180 or a
fibrosarcoma. These changes were accompanied by significant decreases in pantothenate and increases in 4-
phosphopantothenate suggesting an increase in pantothenate kinase activity due to reduction of CoA
inhibition of the enzyme. In contrast, large increases were found in pantothenate and 4-phosphopantothenate
in mice bearing TLX-5 lymphoma, i.p. or s.c. These changes could be due to a large reduction in the rate of
conversion of an intermediate in the pathway of CoA, or increased production of pantothenate or 4-
phosphopantothenate from the degradation of CoA or the phosphopantetheine residue in fatty acid
synthetase. Activities of fatty acid synthetase in liver of mice bearing this tumour showed marked decreases,
but were insufficient to account for the increase in pantothenate, and may reflect a reduction in cytosolic
CoA needed for the conversion of the apo to the holoenzyme.
Metabolic abnormalities are a frequent finding in cancer
patients and tumour-bearing animals. These include
disturbances of lipid metabolism (Kralovic et al., 1977), and
enhanced gluconeogenesis from lactate and amino acids in
liver (Shapot & Blinov, 1974). Enhanced gluconeogenesis
occurs at the expense of high energy compounds such as
ATP produced in liver by the oxidation of fatty acids, and
has been implicated in the pathogenesis of cancer cachexia
(Balducci & Hardy, 1985; Shapot & Blinov, 1974). Some
specific changes however are seen in malnourished animals,
but not in those with experimental cancer, and recently we
showed that in tumour-bearing mice, the hepatic content of
acetyl coenzyme A was significantly decreased. (McAllister et
al., 1982; McAllister & Campbell, 1982). The changes found
in coenzyme A levels in these animals supported an earlier
observation by Rapp (1973) who reported marked reductions
in 'CoA' in various organs of tumour-bearing animals as
well as in liver of a patient with carcinoma of the colon.
Rapp however used a non-specific method of assay which
also measures various metabolites of CoA. These changes
were opposite to those found in starved animals, where the
level of acetyl CoA increases significantly due to increased
oxidation of fatty acids (Smith et al., 1978). In the present
paper we have investigated further the mechanisms involved
in these changes in coenzyme A levels. Coenzyme A
(CoASH) is the metabolically active form of pantothenate,
and is synthesised in mammalian cells from pantothenate, in
the reaction sequence shown below (Figure 1). Pantothenate
is first phosphorylated to give 4-phosphopantothenate by
pantothenate kinase. This then reacts with cysteine to form
4-phosphopantothenylcysteine which is then decarboxylated
to give 4-phosphopantetheine. The latter is then converted in
two further steps to CoASH (Abiko, 1975). Here we have
determined the substrate (pantothenate) and the product (4-
phosphopantothenate) of pantothenate kinase in liver of
mice bearing different tumours. We have also determined the
activity of fatty acid synthetase in these livers since this
enzyme contains a 4-phosphopantetheine residue.
Materials and methods
Three to 4 month old male mice were used throughout. All
animals were weight-matched, and fed a standard cubed diet
with water ad lib. Where the effects of starvation were
studied food, but not water was withdrawn for 24h. TLX-5
lymphoma was maintained by regular i.p. passage in CBA
strain mice every 5 days. Donor animals were killed by
cervical dislocation and tumour cells harvested in Hank's
Balance Salt Medium. Cell suspensions were diluted in the
same medium and counted in a haemocytometer. Groups of
6 mice received 2 x 106 cells in 0.5ml of medium either i.p.
or s.c. in the subscapular region under light ether
anaesthesia. Controls for these groups received 0.5ml of the
medium by the same routes. Sarcoma 180 was maintained in
BALB/c mice. This tumour had been implanted 10 days
previously s.c. in the subscapular region under light ether
anaesthesia. Donor animals were killed by cervical
dislocation, and the tumours dissected free from necrotic
areas, then cut into small pieces (-2mm) which were then
inserted into groups of 6 mice by the same route, also under
anaesthesia. A mouse fibrosarcoma in C57 mice was
maintained in the same way, and by the same route in
groups ofrecipients. Tumour-bearers and their corresponding
controls were killed by cervical dislocation at the following
times after implant: TLX-5 lymphoma, 6 days; sarcoma 180,
10 days and fibrosarcoma groups, 13 days. Livers were
rapidly exposed, and clamped with tongs previously cooled
in liquid nitrogen, then powdered in a mortar also cooled
in liquid nitrogen. Two to three hundred mg powdered tissue
was then placed in preweighed and precooled homogenising
vessels. After a rapid reweighing, 5ml of IM ice-cold
perchloric acid was added, and the mixture homogenised
then centrifuged (2,500g for 10min). The supernatants were
removed, cooled in ice, and the pH adjusted to 6 with 2.5 M
potassium carbonate. After further cooling in ice for 10min
followed by centrifugation (as above), aliquots of the
supernatants were used for the determination of CoASH
and acetyl CoA by a specific enzymatic method (Moellering
& Bergmeyer, 1965). 'Total' CoA by this procedure, refers
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Figure 1 Biosynthesis of coenzyme A (CoASH).
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to the sum of acetyl CoA and CoASH, plus the very small
amounts of oxidised CoA present in liver.
For the assay of pantothenate, 100 to 200mg frozen liver
powder was homogenised with 0.9ml of 8% perchloric acid-
40% ethanol and 0.02ml 1 M dithiothreitol. The mixture was
centrifuged (2,500g), the supernatants removed and cooled
in ice. The pH was then adjusted to 7 with 1 M potassium
carbonate, and after further cooling for Omin, the
perchlorate was removed by centrifugation (2000g). Aliquots
of the supernatants were heated in a boiling water bath for
min cooled and the pantothenate content determined
(Skeggs & Wright, 1944) using lactobacillus plantarum
(ATCC 8014). After 18 to 24h growth in pantothenate assay
medium (Difco Laboratories), turbidities were measured in a
spectrophotometer at 600nm. Standards containing 0 to
0.1 jug pantothenate were included with each batch, and were
linear in this range. For the determination of 4-
phosphopantothenate, aliquots of the neutralised PCA-
ethanol extract were treated with prostatic acid phosphatase
(Brown, 1959). The 'total' pantothenate was then assayed as
above, and the amount of the 4-phospho derivative
determined by difference. Similar groups of control and
tumour-bearing animals were used for the separate
determination of fatty acid synthetase activity in liver. Tissue
was homogenised in 0.1 M phosphate buffer, pH 7,
containing 0.1% by volume of mercaptoethanol, using a
ratio of 1 g liver to 6ml medium. The samples were then
centrifuged at 40,000g for 1 h. Aliquots of the supernatants,
usually 0.04ml were used for the assay by a spectrophoto-
metric method (Lynen, 1962). The cyst(e)ine content of liver
was determined using a specific ninhydrin method (Gationde,
1967) with prior incubation of neutralised perchloric acid
extracts with dithiothreitol to convert cystine to cysteine.
Statistical evaluation of results was determined as the mean
plus or minus the standard error of the mean (SEM) and
significance calculated on the basis of Student's t test.
Results
Growth of TLX-5 lymphoma, either i.p. of s.c. induced a
significant increase (P<0.001) in the levels of both
pantothenate and 4-phosphopantothenate (Figure 2). In
contrast, in mice bearing either sarcoma 180, or the fibro-
sarcoma, the pantothenate levels in liver decreased
significantly, but in both models the 4-phosphopantothenate
content showed significant increases (Figure 3). As can be
seen (Table I) in starved normal mice the pantothenate
content fell to zero, without any significant change in the 4-
phosphopantothenate content. It should be noted, however,
that the sensitivity of the method for pantothenate is
- 0.01 pg.
In agreement with our previous studies (McAllister et al.,
1982), growth of TLX-5 lymphoma i.p. induced significant
decreases in 'total' CoA, acetyl CoA and CoASH. In the
present study, mice growing this tumour s.c. also showed
significant decreases in the levels of these metabolites (Table
II). Also shown are the decreased levels in mice bearing
either Sarcoma 180, or the fibrosarcoma.
The cysteine content of liver of mice bearing the different
tumours did not alter significantly from the corresponding
controls. Values found here for normal mice were
0.094pmolg-1 liver wet weight+s.e.m. 0.037, with little or
no cystine present.
In mice growing TLX-5 i.p. there were highly significant
decreases in the activity of fatty acid synthetase in liver. A
significant decrease (P<0.01) was also found in mice bearing
the fibrosarcoma (Figure 4). In contrast growth of sarcoma
180 induced a significant increase (P<0.001). It will be
noted from the data (Figure 4) that the activity of the
enzyme in liver of normal CBA mice (control group for mice
bearing TLX-5 lymphoma) is considerably higher than in
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Figure 2 The pantothenate and 4-phosphopantothenate of
normal control mice (c) and mice bearing TLX-5 lymphoma (T)
either i.p. or s.c. Values are mean+s.e. of 6 animals in each
group. ***P<0.001.
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Figure 3 The pantothenate and 4-phosphopantothenate content
of livers of normal control mice and mice bearing either sarcoma
180 or a fibrosarcoma (FMT 138). Values are means+s.e. of 6
animals in each group. **=P<0.01; ***=P<0.001.
normal BALB/c or C57/B/6J mice, which were controls for
the sarcoma and fibrosarcoma groups respectively. We have
checked this on several occasions and can only attribute the
difference to some unknown factor in the strain of mice
used.
Discussion
Coenzyme A plays a central role in fatty acid and pyruvate
oxidation, and is the precursor of the 4-phosphopantetheine
residue of fatty acid synthetase (Abiko, 1975). The pathway
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Table I The effect of fasting for 24h on the levels of pantothenate
and 4-phosphopantothenate in mouse livera
Metabolic state Pantothenate 4-Phosphopantothenate
Normal fed. (6) 2.48+0.12 4.13+0.23
Starved 24h (6) n.d. 4.95+0.38
aThe numbers in parentheses give the number of CBA mice in
each group. Values are means+s.e. of duplicate assays and are in
terms of nmolg-1 liver wet wt; n.d. =none detected; limit of
determination ofmethod used is -0.01 ig pantothenate.
Table II The effect of tumour growth in mice on the hepatic
contents of acetyl CoA, CoASH and 'total' CoA
Tumour Acetyl CoA CoASH 'Total' CoA
Control 75.63 +7.76 77.31 +6.27 152.87+5.12
TLX-5 i.p. 37.34+4.10 25.11+ 1.50 62.46+5.54
P<0.001 P<0.001 P<0.001
Control 77.81 +3.28 71.89+2.79 149.70+ 5.03
TLX-5 s.c. 51.85+2.47 47.74+4.16 99.59+3.24
P<0.01 P<0.001 P<0.001
Control 77.10+2.37 77.44+5.49 154.54+6.10
Sarcoma 180 s.c. 53.98+3.59 62.14+2.81 126.14+2.97
P<0.02 P<0.05 P<0.01
Control 70.25+3.10 74.36+4.89 144.61+4.22
FMT s.c. 54.19+2.20 53.92+4.08 108.11+3.20
P<0.01 P<0.01 P<0.001
Six animals were studied in each group. Values are for mean+s.e.
and are expressed in nmolg 1 liver wet wt.
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Figure 4 Fatty acid synthetase activity in liver of normal
control mice and mice brearing TLX-5 lymphoma i.p. or s.c.;
sarcoma 180 or a fibrosarcoma (FMT 138). C=controls;
T=tumour-bearers. Values are means+s.e. of 6 animals in each
group. **=P<0.01; ***=P<0.001. One unit is the amount of
enzyme which under the condition of the assay oxidises 1 pmol
NADPH min-' (corresponding to 0.5,umol malonyl CoA or a
change in extinction of0.004).
of CoA synthesis is known, and it has been shown that
pantothenate kinase may be the regulatory enzyme in this
pathway, since it is subject to feedback inhibition by CoA
(Abiko, 1975), and its activity can be increased by drugs
causing increases in the CoA content of tissues (Skrede &
Halvorsen, 1979). The small, but significant increases in 4-
phosphopantothenate concentrations accompanied by small
but significant increases in pantothenate in livers of mice
bearing either sarcoma 180, or the fibrosarcoma indicate
an increased activity of pantothenate kinase. The reduction
in the hepatic content of CoA in mice bearing sarcoma
180, could give rise to this increased activity as there will
be a reduction in the CoA inhibition of pantothenate
kinase. Large increases in both pantothenate and 4-
phosphopantothenate were found in mice bearing TLX-5
lymphoma either s.c. or i.p. Since we have shown previously
(McAllister et al., 1982), that there are marked reductions in
the food intake of mice bearing this tumour i.p., and Smith
et al. (1978) have reported increases in pantothenate in liver
of starved rats, we examined the effect of starvation in
normal mice on the hepatic content of pantothenate, and 4-
phosphopantothenate. The level of pantothenate fell to zero
in these livers with no change in 4-phosphopantothenate.
The large increases in both of these metabolites in mice
bearing the lymphoma either s.c., or i.p. are in contrast to
the results found with sarcoma 180 or the fibrosarcoma.
These large increases could be due to either a large reduction
in the rate of conversion of a later intermediate in the
pathway to CoA, or a very much larger production of
pantothenate and 4-phosphopantothenate from the
degradation of CoA, or possibly the 4-phosphopantetheine
residue of fatty acid synthetase. The reduction in the hepatic
content of 'total' CoA in mice bearing TLX-5 lymphoma is
of the order of 80nmolg-1 liver wet weight when the
tumour is i.p. and this reduction is more than sufficient to
account for the -40nmol increase in total pantothenate and
4-phosphopantothenate found in these animals. Changes in
the levels of acetyl CoA and CoASH reported here, are in
agreement with our previous findings (McAllister et al.,
1982; 1984). Since the cysteine content of liver did not alter
in the presence of the tumour showed that these changes in
CoA did not depend upon the availability of cysteine. The
degradation of CoA in liver is nearly a reversal of the
biosynthetic route. The initial step is the conversion of CoA
to dephosphocoenzyme A by lysosomal, acid phosphatase,
and the final step the production of pantothenate from
pantetheine catalysed by pantethinase, which is found in
the microsomal-lysosomal fraction (Abiko, 1975). Since
increased activity of lysosomal enzymes have been reported
in tumours, and liver of tumour-bearing animals (Ferguson
et al., 1979) it is possible that this is responsible for the
increased dissimilation of CoA in mice bearing TLX-5
lymphoma.
CoA is the precursor of 4-phosphopantetheine and recent
estimates of the 4-phosphopantetheine content of the enzyme
give values of -2 moles of 4-phosphopantetheine per mole
of enzyme (Qureshi et al., 1975). Thus the activities of
fatty acid synthetase found represent, 7.5-10.1 nmol
4-phosphopantetheine g-1 wet weight of liver in CBA
controls, and 2.4 and 2.6nmolg-1 wet weight in BALB/c
and C57/B/6J mice respectively. The small variations in fatty
acid synthetase activity found in liver of the latter strain of
mouse bearing the fibrosarcoma represent changes of
phosphopantetheine content of about 0.5nmolg-1. The large
changes in activity found in mice bearing TLX-5 lymphoma
represent changes in phosphopantetheine content of 6.5 and
7.3nmolg-1. Thus the 4-phosphopantetheine prosthetic
group of fatty acid synthetase can only contribute a small
amount to any increase in cellular levels of pantothenate and
4-phosphopantothenate. However, the reduction in fatty acid
synthetase activity in mice bearing TLX-5, may be a
reflection of a reduced cytosolic CoA concentration which is
needed for the conversion of apoenzyme to the holo-enzyme
(Qureshi et al., 1975). This is unlikely to be the sole reason,
as mice bearing sarcoma 180 or the fibrosarcoma both
show reduced CoA contents, but only small changes in fatty
acid synthetase activity, and pantothenate and 4-
phosphopantothenate concentrations. It is known that the
synthesis of fatty acid synthetase is regulated by hormones86 R.A. McALLISTER et al.
such as insulin and triiodothyronine (Lornitzo et al., 1981),
and if only TLX-5 lymphoma affected levels of these
hormones then this could explain the differential effects of
this tumour.
At present we have no information on the level of
circulating insulin in these animals, but in rats bearing the
Walker 256 carcinoma, it has been reported that insulin
levels are significantly decreased (Goodlad et al., 1975).
We are aware that in studies such as the present one, the
use of rapidly growing murine tumours may bear little
resemblance to actual changes which occur in humans with
slow growing tumours. However, previously we showed that
in mice bearing a slow growing mammary tumour there were
marked decreases in the levels of CoASH and acetyl CoA in
liver. These changes occurred in animals in which the mean
tumour weight was 16.3mg±s.d.0.003, and only just
palpable in situ. The tumour having been implanted 14 days
previously and represented 0.06% of the host mass
(McAllister et al., 1982).
A further problem in such studies is the provision of
suitable controls. In earlier work (McAllister, 1978) normal
CBA mice were injected with spleen cells from the same
strain of mice to serve as controls for those bearing the
lymphoma. No changes however occurred from normal in
the levels of CoASH and acetyl CoA in liver following this
treatment.
Both animal and human malignancies are known to affect
the vitamin status of the host (Dickerson, 1983). These
changes include uptake of the vitamin by the tumour
(Anthony & Schorah, 1982), and alterations in the
metabolism of the vitamin by the tumour (Rivlin, 1973).
CoA is the metabolically-active form of pantothenate and
our data suggest that growth of these tumours affects
pantothenate metabolism in the host. Of interest is the
observation of Aptekar and Ganetskaia (1965) on riboflavin.
They showed that in mice bearing sarcoma the riboflavin
and riboflavin phosphate levels in liver remained normal, but
the level of flavin adenine dinucleotide, the metabolically
active form of riboflavin fell significantly.
We thank Dr H.G. Nimmo for a gift of rat liver fatty acid
synthetase.
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